{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T14:10:15Z","timestamp":1788099015255,"version":"build-2803163510"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Graves' disease (GD) with onset in childhood or adolescence is a rare disease (ORPHA:525731). Current pharmacotherapeutic approaches use antithyroid drugs, such as carbimazole, as monotherapy or in combination with thyroxine hormone substitutes, such as levothyroxine, as block-and-replace therapy to normalize thyroid function and improve patients' quality of life. However, in the context of fluctuating disease activity, especially during puberty, a considerable proportion of pediatric patients with GD is suffering from thyroid hormone concentrations outside the therapeutic reference ranges. Our main goal was to develop a clinically practical pharmacometrics computer model that characterizes and predicts individual disease activity in children with various severity of GD under pharmacotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospectively collected clinical data from children and adolescents with GD under up to two years of treatment at four different pediatric hospitals in Switzerland were analyzed. Development of the pharmacometrics computer model is based on the non-linear mixed effects approach accounting for inter-individual variability and incorporating individual patient characteristics. Disease severity groups were defined based on free thyroxine (FT4) measurements at diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from 44 children with GD (75% female, median age 11 years, 62% receiving monotherapy) were analyzed. FT4 measurements were collected in 13, 15, and 16 pediatric patients with mild, moderate, or severe GD, with a median FT4 at diagnosis of 59.9 pmol\/l (IQR 48.4, 76.8), and a total of 494 FT4 measurements during a median follow-up of 1.89 years (IQR 1.69, 1.97). We observed no notable difference between severity groups in terms of patient characteristics, daily carbimazole starting doses, and patient years. The final pharmacometrics computer model was developed based on FT4 measurements and on carbimazole or on carbimazole and levothyroxine doses involving two clinically relevant covariate effects: age at diagnosis and disease severity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>We present a tailored pharmacometrics computer model that is able to describe individual FT4 dynamics under both, carbimazole monotherapy and carbimazole\/levothyroxine block-and-replace therapy accounting for inter-individual disease progression and treatment response in children and adolescents with GD. Such clinically practical and predictive computer model has the potential to facilitate and enhance personalized pharmacotherapy in pediatric GD, reducing over- and underdosing and avoiding negative short- and long-term consequences. Prospective randomized validation trials are warranted to further validate and fine-tune computer-supported personalized dosing in pediatric GD and other rare pediatric diseases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1099470","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T04:54:00Z","timestamp":1683089640000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinically practical pharmacometrics computer model to evaluate and personalize pharmacotherapy in pediatric rare diseases: application to Graves' disease"],"prefix":"10.3389","volume":"10","author":[{"given":"Britta","family":"Steffens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"G\u00e4chter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Claude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Gotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freya","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schropp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Janner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"l'Allemand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Konrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Welzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Szinnai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves' disease","volume":"6","author":"Davies","year":"2020","journal-title":"Nat Rev Dis Primer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/ETJ-21-0073","article-title":"2022 European Thyroid Association Guideline for the management of pediatric Graves' disease","author":"Mooij","year":"2022","journal-title":"Eur Thyroid J."},{"key":"B4","unstructured":"Disorders of the thyroid gland\n            PolakM\n            RefetoffS\n            SzinnaiG\n            VlietGV\n          \n            SarafoglouK\n            HoffmannGF\n            RothKS\n          Pediatric Endocrinology and Inborn Errors of Metabolism2017"},{"key":"B5","article-title":"Chapter 83: thyroid disorders","volume-title":"Emery and Rimoin's Essential Medical Genetics","author":"Polak","year":"2013"},{"key":"B6","unstructured":""},{"key":"B7","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-10-0475","article-title":"Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine","volume":"163","author":"Abraham-Nordling","year":"2010","journal-title":"Eur J Endocrinol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000430985","article-title":"Increasing incidence of juvenile thyrotoxicosis in Denmark: a nationwide study, 1998-2012","volume":"84","author":"Kj\u00e6r","year":"2015","journal-title":"Horm Res Paediatr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000500265","article-title":"The incidence of childhood thyrotoxicosis is increasing in both girls and boys in Sweden","volume":"91","author":"Rodanaki","year":"2019","journal-title":"Horm Res Paediatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1530\/EJE-22-0355","article-title":"Spatiotemporal variation of childhood hyperthyroidism: a 10-year nationwide study","volume":"187","author":"Le Moal","year":"2022","journal-title":"Eur J Endocrinol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat Rev Endocrinol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1210\/jc.2008-0842","article-title":"Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment","volume":"93","author":"Kaguelidou","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2265.2009.03717.x","article-title":"Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland","volume":"72","author":"Williamson","year":"2010","journal-title":"Clin Endocrinol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1210\/jc.2009-2495","article-title":"Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study","volume":"95","author":"Boelaert","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2431-6-12","article-title":"Subclinical thyroid disorders and cognitive performance among adolescents in the United States","volume":"6","author":"Wu","year":"2006","journal-title":"BMC Pediatr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0248937","DOI":"10.1371\/journal.pone.0248937","article-title":"Behavioral assessment of children and adolescents with Graves' disease: a prospective study","volume":"16","author":"Hamed","year":"2021","journal-title":"PLoS ONE."},{"key":"B17","doi-asserted-by":"publisher","first-page":"993733","DOI":"10.3389\/fpubh.2022.993733","article-title":"Characteristics of Graves' disease in children and adolescents in Nanjing: a retrospective investigation study","volume":"10","author":"Xie","year":"2022","journal-title":"Front Public Health."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1089\/thy.2016.0044","article-title":"Quality-of-life impairments persist six months after treatment of Graves' hyperthyroidism and toxic nodular goiter: a prospective cohort study","volume":"26","author":"Cramon","year":"2016","journal-title":"Thyroid."},{"key":"B19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1210\/endrev\/bnaa022","article-title":"New therapeutic horizons for graves' hyperthyroidism","volume":"41","author":"Lane","year":"2020","journal-title":"Endocr Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid."},{"key":"B21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1297\/cpe.26.29","article-title":"Guidelines for the treatment of childhood-onset Graves' disease in Japan, 2016","volume":"26","author":"Minamitani","year":"2017","journal-title":"Clin Pediatr Endocrinol Case Rep Clin Investig."},{"key":"B22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1089\/thy.2012.0612","article-title":"Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution","volume":"24","author":"Ohye","year":"2014","journal-title":"Thyroid."},{"key":"B23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/archdischild-2017-313454","article-title":"Long-term outcome of thyrotoxicosis in childhood and adolescence in the west of Scotland: the case for long-term antithyroid treatment and the importance of initial counselling","volume":"103","author":"Kourime","year":"2018","journal-title":"Arch Dis Child."},{"key":"B24","doi-asserted-by":"publisher","first-page":"687834","DOI":"10.3389\/fendo.2021.687834","article-title":"Long-term antithyroid drug treatment of graves' disease in children and adolescents: a 20-year single-center experience","volume":"12","author":"Song","year":"2021","journal-title":"Front Endocrinol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1210\/jc.2009-2546","article-title":"Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children","volume":"95","author":"Rivkees","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"B26","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ando.2018.08.001","article-title":"Graves' disease in children","volume":"79","author":"L\u00e9ger","year":"2018","journal-title":"Ann Endocrinol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1515\/jpem.2011.194","article-title":"Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: efficacy and adverse reactions during initial treatment and long-term outcome","volume":"24","author":"Sato","year":"2011","journal-title":"J Pediatr Endocrinol Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1530\/EJE-20-0617","article-title":"Randomised trial of block and replace vs dose titration thionamide in young people with thyrotoxicosis","volume":"183","author":"Wood","year":"2020","journal-title":"Eur J Endocrinol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/cen.12871","article-title":"Treatment options in the young patient with Graves' disease","volume":"85","author":"Cheetham","year":"2016","journal-title":"Clin Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s40618-016-0477-x","article-title":"Controversies in the management of Graves' disease in children","volume":"39","author":"Rivkees","year":"2016","journal-title":"J Endocrinol Invest."},{"key":"B31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-021-09765-w","article-title":"Modeling of levothyroxine in newborns and infants with congenital hypothyroidism: challenges and opportunities of a rare disease multi-center study","volume":"48","author":"Koch","year":"2021","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"B32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/BF01061691","article-title":"Comparison of four basic models of indirect pharmacodynamic responses","volume":"21","author":"Dayneka","year":"1993","journal-title":"J Pharmacokinet Biopharm."},{"key":"B33","year":"2006"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-03080-7_7","article-title":"Mathematical concepts in pharmacokinetics and pharmacodynamics with application to tumor growth","volume-title":"Nonautonomous Dynamical Systems in the Life Sciences. Lecture Notes in Mathematics","author":"Koch","year":"2013"},{"key":"B35","author":"Gabrielsson","year":"2001","journal-title":"Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications"},{"key":"B36","unstructured":"2014"},{"key":"B37","unstructured":""},{"key":"B38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1365-2125.1980.tb05823.x","article-title":"The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients","volume":"9","author":"Skellern","year":"1980","journal-title":"Br J Clin Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1507\/endocrj1954.33.605","article-title":"Pharmacokinetics of methimazole in normal subjects and hyperthyroid patients","volume":"33","author":"Okamura","year":"1986","journal-title":"Endocrinol Jpn."},{"key":"B40","unstructured":""},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010377629","article-title":"Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development","author":"Wetherington","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010377628","article-title":"Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry","author":"Stone","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jpeds.2017.08.064","article-title":"Caffeine citrate dosing adjustments to assure stable caffeine concentrations in preterm neonates","volume":"191","author":"Koch","year":"2017","journal-title":"J Pediatr."},{"key":"B44","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/jcph.705","article-title":"Pharmacometric approaches to personalize use of primarily renally eliminated antibiotics in preterm and term neonates","volume":"56","author":"Wilbaux","year":"2016","journal-title":"J Clin Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/jcph.852","article-title":"Facilitate treatment adjustment after overdosing: another step toward 21st-century medicine","volume":"57","author":"Koch","year":"2017","journal-title":"J Clin Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/cpt.1456","article-title":"Ivermectin dosing strategy to achieve equivalent exposure coverage in children and adults","volume":"106","author":"Brussee","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10928-016-9490-0","article-title":"Assessment of non-linear combination effect terms for drug-drug interactions","volume":"43","author":"Koch","year":"2016","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"B48","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1210\/jcem-58-3-473","article-title":"Methimazole pharmacology in man: studies using a newly developed radioimmunoassay for methimazole","volume":"58","author":"Cooper","year":"1984","journal-title":"J Clin Endocrinol Metab."},{"key":"B49","unstructured":"Introduction to Population Pharmacokinetic \/ Pharmacodynamic Analysis with Nonlinear Mixed Effects Models | Wiley. J. Wiley & Sons\n            OwenJS\n            Friedler-KellyJ\n          2014"},{"key":"B50","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1530\/EJE-21-0077","article-title":"Methimazole-induced remission rates in pediatric Graves' disease: a systematic review","volume":"185","author":"van Lieshout","year":"2021","journal-title":"Eur J Endocrinol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/009286150103500117","article-title":"Some issues concerning the normalization of laboratory data based on reference ranges","volume":"35","author":"Chuang-Stein","year":"2001","journal-title":"Drug Inf J DIJ Drug Inf Assoc."},{"key":"B52","first-page":"284","article-title":"Quantitative aspects of iodine metabolism in man","volume":"4","author":"Riggs","year":"1952","journal-title":"Pharmacol Rev."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02477840","article-title":"The thyroid-pituitary homeostatic mechanism","volume":"18","author":"Danziger","year":"1956","journal-title":"Bull Math Biophys."},{"key":"B54","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0025-5564(78)90094-9","article-title":"Optimal control policies for the prescription of thyroid hormones","volume":"42","author":"Mak","year":"1978","journal-title":"Math Biosci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.mbs.2007.10.009","article-title":"computational model of the human thyroid","volume":"212","author":"Degon","year":"2008","journal-title":"Math Biosci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10492-006-0020-z","article-title":"A mathematical model describing the thyroid-pituitary axis with time delays in hormone transportation","volume":"51","author":"Mukhopadhyay","year":"2006","journal-title":"Appl Math."},{"key":"B57","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jtbi.2007.05.016","article-title":"A mathematical model of pituitary\u2013thyroid interaction to provide an insight into the nature of the thyrotropin\u2013thyroid hormone relationship","volume":"248","author":"Leow","year":"2007","journal-title":"J Theor Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1089\/thy.2007.0388","article-title":"Extensions, validation, and clinical applications of a feedback control system simulator of the hypothalamo-pituitary-thyroid axis","volume":"18","author":"Eisenberg","year":"2008","journal-title":"Thyroid."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s11095-013-0989-4","article-title":"Systems pharmacology modeling of drug-induced modulation of thyroid hormones in dogs and translation to human","volume":"30","author":"Ekerot","year":"2013","journal-title":"Pharm Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11154-016-9386-8","article-title":"Relapse prediction in Graves' disease: towards mathematical modeling of clinical, immune and genetic markers","volume":"17","author":"Langenstein","year":"2016","journal-title":"Rev Endocr Metab Disord."},{"key":"B61","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fendo.2018.00091","article-title":"Mathematical modeling of the pituitary\u2013thyroid feedback loop: role of a TSH-T3-shunt and sensitivity analysis","volume":"9","author":"Berberich","year":"2018","journal-title":"Front Endocrinol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12976-017-0073-6","article-title":"A patient-specific treatment model for Graves' hyperthyroidism","volume":"15","author":"Pandiyan","year":"2018","journal-title":"Theor Biol Med Model."},{"key":"B63","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s10957-021-01819-w","article-title":"OptiDose: computing the individualized optimal drug dosing regimen using optimal control","volume":"189","author":"Bachmann","year":"2021","journal-title":"J Optim Theory Appl."},{"key":"B64","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/17512433.2017.1251837","article-title":"Pharmacometrics-based decision tools facilitate mHealth implementation","volume":"10","author":"Nekka","year":"2017","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1210\/clinem\/dgaa373","article-title":"Approach to the patient with thyrotoxicosis using telemedicine","volume":"105","author":"Griffith","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"B66","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jadohealth.2022.03.021","article-title":"Wearable technology leads to initial workup of Graves' Disease in an adolescent female","volume":"71","author":"Shanefield","year":"2022","journal-title":"J Adolesc Health."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.2196\/mhealth.9884","article-title":"Clinical feasibility of monitoring resting heart rate using a wearable activity tracker in patients with thyrotoxicosis: prospective longitudinal observational study","volume":"6","author":"Lee","year":"2018","journal-title":"JMIR MHealth UHealth."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1099470\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T04:54:06Z","timestamp":1683089646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1099470\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":67,"alternative-id":["10.3389\/fmed.2023.1099470"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1099470","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"article-number":"1099470"}}